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The Third International Research Workshop on Alopecia Areata
was held in Washington DC on November 5, 1998. The conference
was organized jointly by the National Alopecia Areata Foundation
and the National Institute of Arthritis and Musculoskeletal and
Skin Diseases with organizers Vera H. Price, Alan Moshell, Kurt
S. Stenn, Madeleine Duvic, Lowell A. Goldsmith, Michael J.
Cork, and Rudolf Happle. The Workshop brought together
dermatologists, immunologists, geneticists, molecular biologists,
biochemists, and pathologists for an open exchange of recent
advances in alopecia areata, which is an autoimmune disease that
causes hair loss. Over 250 individuals from 21 countries in Europe,
North and South America, Asia, and the Middle East attended the
1 day meeting. This was a significant increase in participation over
the Second International Research Workshop on Alopecia Areata
held in 1994. Fourteen speakers gave seminars, and 33 posters were
available for review on wide-ranging aspects of hair biology and
alopecia areata. The format of the Workshop stimulated enthusiastic
interaction and discussion among all the participants who repres-
ented academia, government, and the pharmaceutical industry.
ANIMAL MODELS FOR ALOPECIA AREATA
The Smyth chicken model, derived from the SL strain, was
identified as a new animal model for alopecia areata (AA). Normally
pigmented feathers gradually lose color with age in association with
nonscarring inflammation similar to vitiligo. It was noted that some
chickens with vitiligo also develop feather loss. The loss is patchy
and may expand over time and become universal in some chickens.
This new model may help in identifying AA susceptibility genes
and may suggest a link between vitiligo, melanogenesis, and
development of AA.
The C3H/HeJ mouse model for AA was discovered shortly after
the First International Research Workshop on AA. Up to 20%
of C3H/HeJ mice spontaneously develop patchy nonscarring
inflammatory alopecia (Sundberg et al, 1994). AA-like hair loss has
now been discovered in other mouse strains including A/J, CBA/
CaHN-Btkxid/J, BALB/2R-H2h2/Lil, and HRS/J heterozygotes.
Different animal models may represent different forms of human
AA and analysis of these mouse strains may identify AA susceptibility
genes common or unique to each. This information could illuminate
the themes common to all forms of AA and help delineate
subcategories.
Whereas significant advances were made in defining the nature
of animal models with spontaneous AA, induced AA mouse models
were also demonstrated. Skin grafts from affected C3H/HeJ mice
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could be given to normal haired recipients who then developed
AA 8–10 weeks after grafting. Investigators also noted that AA
could be induced by taking skin-draining lymph node cells from
AA affected mice and transferring them to normal haired recipients.
Again, hair loss developed 8–10 weeks after the procedure indicating
inflammatory cells are capable of inducing hair loss even though
hair follicles are potentially immune-privileged sites. This consistent
model will be useful to examine what happens in the system before
overt hair loss occurs. The ability to induce AA in a model also
suggests that whereas individuals may be genetically predisposed
towards AA, just having susceptibility genes does not guarantee
that the individual will develop the disease. This AA induction
technique can also be used to produce large numbers of mice for
AA treatment evaluation.
The importance of inflammatory cells in AA has previously been
demonstrated using a nude mouse model (Gilhar and Kreuger,
1987, 1992, 1998). Human AA-affected skin grafted to nude mice
regrew hair indicating a systemic factor blocks hair growth rather
than localized dysfunction of hair follicles. Inflammatory cells taken
from AA-affected patients, isolated into different cell types and
injected into the grafts of now regrown hair were shown to promote
renewed hair loss. CD81 cytotoxic T cells were particularly potent
in their direct action on the hair follicles. These animal model
studies provide the first indirect evidence of inflammatory cell
mediation of AA and suggest that hair follicle specific auto-
antibodies (McElwee et al, 1996; Tobin et al, 1997a) may not be
fundamentally required for AA development.
In organ-specific autoimmune diseases the inflammatory response
is directed to just a few antigenic epitopes and in turn only those
T lymphocytes specific for these antigens are directly involved in
disease pathogenesis. Epitope spreading may lead to a broader
spectrum of target antigens involved in chronic disease perpetuation
(Chan et al, 1998). Lymphocyte cells from C3H/HeJ mice with
AA were screened and T cell clones expressing a Vβ8.2/Jβ2.5 T cell
receptor arrangement predominated. The receptor arrangement of
these cell clones may be characterized further and this may help to
identify the nature of targeted antigen(s) during initial onset and
later in chronic lesions.
The collected work of several research groups on cell-mediated
activity in AA may eventually lead to new treatments directed
against specific pathogenic inflammatory cell subsets. Clearly, animal
models will provide an important tool in the investigation of
genetic and environmental activation factors, disease pathogenesis,
and development of new and improved treatment protocols.
GENETICS OF AA
A preliminary study using C3H/HeJ mice examined potential
chromosome locations that may contain genes involved in AA
and/or in high immunoglobulin production. Three gene loci were
identified one of which was common to both high immunoglobulin
concentration and AA susceptibility. A region of mouse chromo-
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some 6 may contain one or more genes involved in inflammatory
events associated with AA. Intriguingly, a separate investigation
looking at human AA independently identified the equivalent
chromosome region (2p12–13) as being a location for AA suscepti-
bility gene(s). Investigators indicated IL-1 receptor gene poly-
morphism was involved (Cork et al, 1996). Candidate genes in
this chromosome region are being reviewed for their potential
involvement in both human and murine AA.
The association of specific human leukocyte antigens (HLA)
with autoimmune disease may involve molecular and structural
features of the HLA peptide-binding site and/or a general predis-
position to overexpression of HLA antigens on target tissue and
antigen-presenting cells (Hang and Nakamura, 1997). Two separate
investigations independently confirmed the presence of specific
HLA antigens in association with AA. The broad HLA antigen
DQ3 was identified as a general susceptibility HLA antigen for
AA. HLA alleles DQB1*0301, DRB1*0401, and DRB1*1104
were found in highly significantly increased frequency in people
with alopecia totalis/alopecia universalis. DRB1*1104 was also
found with significantly increased frequency in those with patchy
AA but the other two alleles were not. The investigators suggested
that amino acid sequencing of the antigen binding grooves of these
HLA antigens may indicate the structure and identity of the elusive
AA target antigens. Investigators also suggested DRB3*52a may
confer resistance to AA.
Clearly, AA is a polygenic susceptibility based disease involving
complex gene interaction and environmental modification. Under-
standing the genetics behind AA will help explain the disease
activation process, may identify susceptible subgroups in the general
population, and in the long term may eventually lead to a treatment
involving gene therapy.
HAIR FOLLICLE FUNCTION
Immune privilege may play an important part in AA (Paus et al,
1993; Paus, 1997). Some research groups are trying to understand
transient immune privilege of the hair follicle and how this
protection might break down in AA. Researchers have noted that
major histocompatibility complex (MHC) class I and class II
antigens are not expressed in normal hair follicles (Paus et al, 1993;
Paus, 1997). They have also shown that immunosuppressants
such as α-melanocyte-stimulating hormone, adrenocorticotropic
hormone, and transforming growth factor β are produced locally
in hair follicles and this may further bolster hair follicle immune
privilege. The investigators hypothesize there might be upregulation
of MHC antigens and/or downregulation of locally produced
immunosuppressants and this may allow the immune system to
recognize hair follicle antigens leading to onset of AA. Further
work on natural immunosuppressants is in progress.
Key genes involved in hair growth and cycling are of increasing
interest and will help us understand how hair follicles function
and why they may be disrupted in various hair loss conditions.
Investigators have identified several families from Pakistan and
Ireland with the hairless gene trait equivalent of the hairless IRS/
3 mouse (Ahmad et al, 1998). Investigators confirmed that the
human hairless gene is associated with a disease now called
generalized atrichia and/or atrichia with papules, and erroneously
described in previous reports as alopecia universalis congenita.
People with the hairless gene are born with hair which is then
permanently lost during the first 3 mo of life. It was shown that
people with a hairless gene had massive and premature apoptosis
in the hair matrix cells suggesting that hair cycling into catagen is
totally and irreversibly disrupted. Most intriguingly, the investigators
have begun to screen people previously diagnosed as having
inflammatory alopecia universalis, who permanently lost all scalp
and body hair within the first 3 mo of life, and have found a very
small number who apparently have a variation of the hairless gene
defect. This is a reminder of the potential for misdiagnosis of AA
and emphasizes the need for a simple diagnostic test.
We know that Hox genes are important in defining the position,
density, and development of hair follicles in an embryo as well as
being involved in growth of the limbs, eyes, and nails. Hoxc13
seems to be involved in controlling several gene products most
notably hair keratins. Transgenic mice targeted for Hoxc13 defi-
ciency were found unable to synthesize correctly hair keratins.
Clinically, the mice had sparse, brittle hair, brittle tongue papillae,
and misshaped, overgrown nails. Identifying genes involved in
normal hair follicle function and those important in AA susceptibility
will provide an understanding of the potential mechanisms involved
in hair disease.
TREATMENTS
Clinical dermatologists at the Second International Research Work-
shop on AA in 1994 were asked to complete a questionnaire about
how they treat AA. In total 38 different treatments including
combination treatments were in use 4 years ago. The most common
treatment was use of intralesional corticosteroids for adults and
topical corticosteroids for children. Extensive AA was most
frequently treated with a contact sensitizing agent such as: diphenyl-
cyclopropenone, squaric acid dibutyl ester, and dinitrochloroben-
zene. The therapy protocols varied markedly in composition,
concentration, and delivery, indicating personal preference of the
dermatologist plays a significant part in how AA is treated. Studies
to identify superior, new treatments are urgently required.
Animal models are now used in research for new and improved
treatments (McElwee et al, 1997). The drug Leflunomide is
an immunosuppressant used to treat rheumatoid arthritis that
acts to block IL-2 cytokine activity. The drug was given orally
to Dundee Experimental Bald Rats and was found to promote
limited hair growth. Some rats responded much better than
others and whereas some had good hair regrowth others
responded with little or no regrowth. Leflunomide may not be
a superior therapy for AA but the project demonstrates the
potential for animal models in rapid treatment evaluation. Rodent
models were also subjected to treatment with the topical contact
sensitizers diphenylcyclopropenone and squaric acid dibutyl ester
yielding a variable hair regrowth response similar to that observed
in humans. CD44v10 is involved in activating CD41 and CD81
cells to migrate into tissue and attack antigenic targets. Normal
C3H/HeJ mice grafted with AA affected skin to induce AA in
the recipient were given an anti-CD44v10 specific monoclonal
antibody shortly after surgery. It was shown that induction of
AA could be blocked using this monoclonal antibody. Use of
CD44v10 in humans may not be practical but the experiment
points towards CD41 and/or CD81 cells being the key
pathogenic cell subsets in AA.
THE FUTURE OF AA
Research has progressed considerably in the 4 years since the
Second International Research Workshop on AA. We have now
drawn the conclusion that while auto-antibodies may play an
important part in disease, they are probably not the fundamental
cause of AA. Investigations are much more focused and directed
towards the understanding of AA pathogenesis and demonstration
of AA as an autoimmune, cell-mediated disease. Using animal
models, investigators are homing in on inflammatory cells as
promoters of hair loss. The CD81 T cell type in particular is
receiving attention as the candidate key pathogenic cells with
CD41 cells in their classic helper/supporter role. Genetics research
has now begun in earnest. New chromosome locations beyond the
HLA region have been suggested as potential areas harboring AA
susceptibility genes. Genetic research may ultimately explain why,
how, and who develops AA.
Hair follicle function, immune system activity, and genetic
susceptibility in AA are all receiving interest from laboratory
investigators. One clearly neglected area of research, however, is
defining the disease induction process and activation factors
involved, particularly contributions from the environment. The
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confounding variables that may influence onset, severity, and
duration of AA must be systematically examined. Most investigators
now realize that AA is not a homogeneous disease. Different forms
of AA may indicate different genetic and environmental factor
contributions. Different presentations may also indicate future
prognoses and response to treatment.
The need for universally accepted criteria to select subjects for
clinical and basic laboratory studies of AA was recognized after the
1994 Workshop. As a result the National Alopecia Areata Founda-
tion sponsored an AA consensus meeting in Brussels in 1995
to establish investigational guidelines to facilitate collaborations,
comparison of data, and sharing of patient-derived tissue. A central
repository for clinical data and a DNA/tissue bank for patients with
AA accessible to all investigators will be established. The AA
investigation guidelines were presented at the Third International
Research Workshop and are being published in the Journal of the
American Academy of Dermatology.
To help guide future AA research the Workshop included keynote
speakers Kai Wucherpfennig and Edward Wakeland reviewing the
latest developments in their respective fields of molecular mimicry
in T cell mediated autoimmunity, and genetic dissection of auto-
immune pathogenesis in murine lupus nephritis. Investigators
involved in AA research will need to monitor such relevant and
well-funded fields, learn from their mistakes, and adapt research
protocols to accelerate our understanding of AA.
In 4 years time, the Fourth International Research Workshop
on AA may reveal a hypothetical framework for the induction
and progression of AA with essential supporting evidence in
place including: identification of the antigenic epitope(s) targeted
by inflammatory cells in AA, identification of pathogenic T cell
subsets, and the ability to induce AA in models by transfer of
lymphocyte subsets, antibodies, and/or antigen epitopes. Patho-
genic cell groups may be characterized for their receptors and
process of activation. Multiple susceptibility and severity modifying
gene loci may be identified if not the actual gene functions
involved in AA. Although few new treatments were reported
at this Workshop, the development of animal models with the
potential for screening new therapies has gained the attention
of several academic centers and pharmaceutical companies. Future
Workshops will reveal new treatments with improved success
rates and fewer side-effects. Understanding disease pathogenesis
will reveal key links in the process that can be targeted with
new, specific interventions.
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